Role of chemotherapy resistance genes in outcome of neuroblastoma

Pediatric Blood and Cancer

Volumn 48, Issue 3, 2007, Pages 311-317

  De Cremoux, Patricia ^a   Jourdan Da Silva, Nathalie ^a   Couturier, Jérôme ^a   Tran Perennou, Carine ^a   Schleiermacher, Gudrun ^a   Fehlbaum, Pascale ^a   Doz, François ^a   Mosseri, Véronique ^a   Delattre, Olivier ^a   Klijanienko, Jerzy ^a   Vielh, Philippe ^a   Michon, Jean ^a  

^a INSTITUT CURIE   (France)

Author keywords

Neuroblastoma; Predictive factors; Quantitative RT PCR

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; LRP GENE; MALE; MDR1 GENE; MRP1 GENE; MRP5 GENE; MULTIDRUG RESISTANCE; NEUROBLASTOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CISPLATIN; COMPUTER SYSTEMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GENE EXPRESSION PROFILING; GENES, MDR; GENES, MYC; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEUROBLASTOMA; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; S PHASE; TREATMENT OUTCOME; VAULT RIBONUCLEOPROTEIN PARTICLES; VINCRISTINE;

EID: 33846903310     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20853     Document Type: Article

References (50)

1. Bernstein ML, Leclerc JM, Bunin G, et al. A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 1992;10:323-329.
2. De Bernardi B, Conte M, Mancini A, et al. Localized resectable neuroblastoma: Results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 1995;13:884-893.
3. Rubie H, Coze C, Plantaz D, et al. Localised and unresectable neuroblastoma in infants: Excellent outcome with low-dose primary chemotherapy. Br J Cancer 2003;89:1605-1609.
4. Schleiermacher G, Rubie H, Hartmann O, et al. Treatment of stage 4s neuroblastoma-report of 10 years' experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer 2003;89:470-476.
5. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116.
6. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-2279.
7. Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004;10:4-12.
8. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 2005;3:6466-6473.
9. Kaneko Y, Kobayashi H, Watanabe N, et al. Biology of neuroblastomas that were found by mass screening at 6 months of age in Japan. Pediatr Blood Cancer 2005; [Epub ahead of print].
10. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
11. Ling V. Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40:S3-S8.
12. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003;22:7496-7511.
13. Kedersha NL, Rome LH. Isolation and characterization of a novel ribonucleoprotein particle: Large structures contain a single species of small RNA. J Cell Biol 1986;103:699-709.
14. Mossink MH, van Zon A, Scheper RJ, et al. Vaults: A ribonucleoprotein particle involved in drug resistance? Oncogene 2003;22:7458-7467.
15. Foley GE, Lazarus H, Farber S, et al. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965;18:522-529.
16. Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 1979;39:2070-2076.
17. Coze C, Hartmann O, Michon J, et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology. J Clin Oncol 1997;15:3433-3440.
18. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000;18:468-476.
19. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
20. de Cremoux P, Thioux M, Peter M, et al. Polymerase chain reaction compared with dot blotting for the determination of N-myc gene amplification in neuroblastoma. Int J Cancer 1997;72:518-521.
21. Schleiermacher G, Janoueix-Lerosey I, Combaret V, et al. Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet 2003;141:32-42.
22. El-Naggar AK, Vielh P. Solid tumor DNA content analysis. Methods Mol Biol 2004;263:355-370.
23. Valteau-Couanet D, Michon J, Boneu A, et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005;23:532-540.
24. Minard V, Hartmann O, Peyroulet MC, et al. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: Results of the French society of pediatric oncology. Br J Cancer 2000;83:973-979.
25. Solary E, Drenou B, Campos L, et al. Quinine as a multidrug resistance inhibitor: A phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003;102:1202-1210.
26. de Cremoux P, Tran-Perennou C, Elie C, et al. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol 2002;64:507-515.
27. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977;35:1-39.
28. Castleberry RP. Predicting outcome in neuroblastoma. N Engl J Med 1999;340:1992-1993.
29. Castel V, Garcia-Miguel P, Canete A, et al. Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting. Eur J Cancer 1999;35:606-611.
30. Castleberry RP, Pritchard J, Ambros P, et al. The International Neuroblastoma Risk Groups (INRG): A preliminary report. Eur J Cancer 1997;33:2113-2116.
31. London W, Castleberry R, Matthay K, et al. Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group. Jpn J Clin Oncol 2005;23:1-7 [Epub ahead of print].
32. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
33. Maris JM, Guo C, Blake D, et al. Comprehensive analysis of chromosome Ip deletions in neuroblastoma. Med Pediatr Oncol 2001;36:32-36.
34. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216.
35. Perel Y, Valteau-Couanet D, Michon J, et al. Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use. Arch Pediatr 2004;11:834-842.
36. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-424,
37. Sparreboom A, Danesi R, Ando Y, et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003;6:71-84.
38. Liedert B, Materna V, Schadendorf D, et al. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003;121:172-176.
39. Filipits M, Pohl G, Stranzl T, et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998;91:1508-1513.
40. Chan HS, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-1614.
41. Lu Q, Li X, Zhang J, et al. [Expression of glutathione S-transferase, P-glycoprotein, and multidrug resistance-associated protein in neuroblastoma and its clinical significance]. Zhonghua Bing Li Xue Za Zhi 2002;31:506-509.
42. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334:231-238.
43. Oda Y, Rose I, Radig K, et al. Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours. Virchows Arch 1997;430:99-105.
44. Dhooge CR, De Moerloose BM, Benoit YC, et al. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma. Cancer 1997;80:1250-1257.
45. Haber M, Bordow SB, Haber PS, et al. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer 1997;33:2031-2036.
46. Bordow SB, Haber M, Madafiglio J, et al. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 1994;54:5036-5040.
47. Norris MD, Burkhart CA, Marshall GM, et al. Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol 2000;35:585-589.
48. Norris MD, Smith J, Tanabe K, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther 2005;4:547-553.
49. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-2491.
50. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999;23:789-795.